Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

74.79
-0.8700-1.15%
Post-market: 74.40-0.3900-0.52%19:51 EDT
Volume:1.89M
Turnover:141.72M
Market Cap:12.35B
PE:-31.42
High:76.00
Open:75.15
Low:74.54
Close:75.66
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:0.71
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.80%
ROA:-7.31%
PB:25.26
PE(LYR):-31.41

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Healthequity (HQY), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Ionis Pharmaceuticals (IONS) and DENTSPLY SIRONA (XRAY)

TIPRANKS
·
Jan 16

RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 14

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

TIPRANKS
·
Jan 14

BRIEF-Biogen Says Co Received European Commission Approval For High Dose Regimen Of SPINRAZA

Reuters
·
Jan 13

Biogen Receives European Commission Approval for High Dose Regimen of Spinraza® (Nusinersen) for Spinal Muscular Atrophy

THOMSON REUTERS
·
Jan 13

Biogen - High Dose Spinraza Approved in Japan, Decision Expected by April 3, 2026

THOMSON REUTERS
·
Jan 13

Ionis Pharmaceuticals raises TRYNGOLZA peak sales guidance to over $2 billion for sHTG

Reuters
·
Jan 12

Ionis Pharmaceuticals Announces 2025 Achievements and Outlines 2026 Milestones

Reuters
·
Jan 12

Ionis Pharmaceuticals EVP Shannon L. Devers Reports Sale of Common Shares

Reuters
·
Jan 10

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's

Reuters
·
Jan 08

BUZZ-Ionis hits seven-year high after partner GSK reveals promising hepatitis B trial results

Reuters
·
Jan 08

GSK's chronic hepatitis B therapy shows promise in key studies, analysts await full data

Reuters
·
Jan 07

Ionis and GSK Report Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B

Reuters
·
Jan 07

Ionis Partner GSK Announces Positive Topline Results From B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen, a Potential First-in-Class Medicine for Chronic Hepatitis B

THOMSON REUTERS
·
Jan 07

Ionis Pharmaceuticals EVP Research Eric Swayze Reports Sale of Common Shares

Reuters
·
Jan 07

Ionis Pharmaceuticals Files Initial Beneficial Ownership Statement for Holly B. Kordasiewicz, EVP and Chief Development Officer

Reuters
·
Jan 07

Ionis Pharmaceuticals CEO to Present Company Overview at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

Assessing Ionis Pharmaceuticals (IONS) Valuation After Analyst Optimism And FDA Approval Of Tryngolza

Simply Wall St.
·
Jan 06

Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jan 06